Loading Events

Using testosterone to treat prostate cancer


Lab Head, Department of Anatomy and Developmental Biology and Biomedicine Discovery Institute, Monash University



Passcode: 929947

CL_16 Rainforest Walk, Room S11, Theatre (Bldg 25)


The standard treatment for advanced prostate cancer is ongoing suppression of the androgen receptor pathway. The limitations of this approach are that tumours develop diverse mechanisms of resistance and patients experience mounting side-effects. Another emerging treatment for advanced prostate cancer, known as bipolar androgen therapy (BAT), involves oscillations between suppression and over-activation of the androgen receptor pathway. This presentation will focus on my lab’s preclinical studies of bipolar androgen therapy using patient-derived models of prostate cancer from the Melbourne Urological Research Alliance.


Dr Mitchell Lawrence is a Laboratory Head in the Department of Anatomy and Developmental Biology and Biomedicine Discovery Institute, Monash University. His research on prostate cancer begins and ends with patients. Working with patient advocates, support groups, community organisations and clinicians, Dr Lawrence identifies critical clinical challenges facing patients. He tackles these challenges through multidisciplinary studies into tumour biology, pathology, and novel therapies. In collaboration with the Melbourne Urological Research Alliance, Dr Lawrence is using patient-derived models to uncover why some patients’ tumours are more aggressive than others and to identify how to treat these tumours more effectively. This is leading to changes in international clinical practice, concurrent clinical trials, and partnerships with industry.

Share This Story, Choose Your Platform!